EBITDA Margin: 33.70%
Is the EBITDA margin high or low?
The EBITDA margin of 33.70% is in line with its 5-year average of 31.53%, near the high end of its 5-year range (25.63%–35.86%).
As of Sunday, June 28, 2026. 11.55% above its 12-month average of 30.21%.
EW EBITDA Margin
Reported quarterly EBITDA margin; no daily interpolation.
EW Average EBITDA Margin Chart
EW Current vs Average EBITDA Margin Chart
EW EBITDA Margin Metrics
EBITDA MARGIN
33.70%
EBITDA MARGIN AVG TTM
30.21%
EBITDA MARGIN AVG 3Y
30.20%
EBITDA MARGIN AVG 5Y
31.53%
EBITDA MARGIN AVG 10Y
31.29%
EBITDA MARGIN AVG 15Y
29.12%
EBITDA MARGIN AVG 20Y
27.40%
CURRENT VS TTM AVG
+11.55%
CURRENT VS 3Y AVG
+11.58%
CURRENT VS 5Y AVG
+6.88%
CURRENT VS 10Y AVG
+7.71%
CURRENT VS 15Y AVG
+15.74%
CURRENT VS 20Y AVG
+23.02%
EW Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation (EW) | $52.27B | 33.70% | 30.21% | 30.20% | 31.53% |
| Cencora, Inc. (COR)vs › | $55.67B | 1.46% | 1.44% | 1.41% | 1.40% |
| Cardinal Health, Inc. (CAH)vs › | $55.72B | 1.38% | 1.12% | 0.75% | 0.28% |
| Becton, Dickinson and Company (BDX)vs › | $56.49B | 23.08% | 23.14% | 23.23% | 22.53% |
| Humana Inc. (HUM)vs › | $46.08B | 1.76% | 1.98% | 3.17% | 4.08% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $43.50B | 34.08% | 33.18% | 32.37% | 31.82% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $65.20B | 28.74% | 30.12% | 35.91% | 41.00% |
| Boston Scientific Corporation (BSX)vs › | $65.74B | 26.60% | 24.95% | 24.24% | 23.28% |
| Agilent Technologies, Inc. (A)vs › | $38.41B | 25.43% | 26.12% | 26.05% | 25.37% |
| Medline Inc. (MDLN)vs › | $32.87B | 10.26% | 11.41% | 10.38% | 10.38% |
Margin Comparison
Gross Margin
78.0%
EBITDA Margin
33.7%
Operating Margin
27.6%
Net Margin
17.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EBITDA Margin FAQ
- What is the EBITDA margin for Edwards Lifesciences Corporation (EW)?
- The EBITDA margin for EW stock is 33.70%.
- Is Edwards Lifesciences Corporation's EBITDA margin high or low?
- The EBITDA margin of 33.70% is in line with its 5-year average of 31.53%, near the high end of its 5-year range (25.63%–35.86%).
- What is the TTM average EBITDA margin for Edwards Lifesciences Corporation (EW)?
- The TTM average EBITDA margin for EW stock is 30.21%.
- What is the 3Y average EBITDA margin for Edwards Lifesciences Corporation (EW)?
- The 3Y average EBITDA margin for EW stock is 30.20%.
- What is the 5Y average EBITDA margin for Edwards Lifesciences Corporation (EW)?
- The 5Y average EBITDA margin for EW stock is 31.53%.
- What is the 10Y average EBITDA margin for Edwards Lifesciences Corporation (EW)?
- The 10Y average EBITDA margin for EW stock is 31.29%.
- What is the 15Y average EBITDA margin for Edwards Lifesciences Corporation (EW)?
- The 15Y average EBITDA margin for EW stock is 29.12%.
- What is the 20Y average EBITDA margin for Edwards Lifesciences Corporation (EW)?
- The 20Y average EBITDA margin for EW stock is 27.40%.
EW EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | 33.70% |
| 2025-12-31 | 26.31% |
| 2025-09-30 | 29.90% |
| 2025-06-30 | 30.61% |
| 2025-03-31 | 30.54% |
| 2024-12-31 | 25.63% |
| 2024-09-30 | 28.43% |
| 2024-06-30 | 29.17% |
| 2024-03-31 | 29.63% |
| 2023-12-31 | 31.06% |
| 2023-09-30 | 30.83% |
| 2023-06-30 | 31.39% |
| 2023-03-31 | 30.47% |
| 2022-12-31 | 33.49% |
| 2022-09-30 | 35.58% |
| 2022-06-30 | 34.16% |
| 2022-03-31 | 35.60% |
| 2021-12-31 | 30.22% |
| 2021-09-30 | 34.19% |
| 2021-06-30 | 35.86% |
| 2021-03-31 | 35.39% |
| 2020-12-31 | 33.77% |
| 2020-09-30 | 33.66% |
| 2020-06-30 | 27.28% |
| 2020-03-31 | 34.79% |
| 2019-12-31 | 31.31% |
| 2019-09-30 | 28.93% |
| 2019-06-30 | 27.46% |
| 2019-03-31 | 33.02% |
| 2018-12-31 | 31.71% |
| 2018-09-30 | 30.29% |
| 2018-06-30 | 31.94% |
| 2018-03-31 | 31.71% |
| 2017-12-31 | 29.56% |
| 2017-09-30 | 29.06% |
| 2017-06-30 | 32.51% |
| 2017-03-31 | 37.20% |
| 2016-12-31 | 29.70% |
| 2016-09-30 | 29.35% |
| 2016-06-30 | 26.16% |
| 2016-03-31 | 31.23% |
| 2015-12-31 | 28.19% |
| 2015-09-30 | 28.32% |
| 2015-06-30 | 26.52% |
| 2015-03-31 | 30.73% |
| 2014-12-31 | 25.66% |
| 2014-09-30 | 24.28% |
| 2014-06-30 | 23.54% |
| 2014-03-31 | 21.00% |
| 2013-12-31 | 26.16% |
| 2013-09-30 | 24.17% |
| 2013-06-30 | 26.76% |
| 2013-03-31 | 25.13% |
| 2012-12-31 | 28.80% |
| 2012-09-30 | 24.34% |
| 2012-06-30 | 22.78% |
| 2012-03-31 | 21.76% |
| 2011-12-31 | 23.55% |
| 2011-09-30 | 17.88% |
| 2011-06-30 | 20.90% |
| 2011-03-31 | 22.97% |
| 2010-12-31 | 24.46% |
| 2010-09-30 | 23.16% |
| 2010-06-30 | 23.90% |
| 2010-03-31 | 22.53% |
| 2009-12-31 | 22.67% |
| 2009-09-30 | 22.04% |
| 2009-06-30 | 23.07% |
| 2009-03-31 | 21.98% |
| 2008-12-31 | 22.34% |
| 2008-09-30 | 19.14% |
| 2008-06-30 | 20.36% |
| 2008-03-31 | 16.24% |
| 2007-12-31 | 20.17% |
| 2007-09-30 | 19.36% |
| 2007-06-30 | 22.30% |
| 2007-03-31 | 21.96% |
| 2006-12-31 | 21.72% |
| 2006-09-30 | 21.83% |
| 2006-06-30 | 22.48% |
| 2006-03-31 | 31.13% |
| 2005-12-31 | 24.67% |
| 2005-09-30 | 22.46% |
| 2005-06-30 | 23.32% |
| 2005-03-31 | 22.56% |
| 2004-12-31 | 22.94% |
| 2004-09-30 | 22.51% |
| 2004-06-30 | 22.76% |
| 2004-03-31 | 15.45% |
| 2003-12-31 | 22.62% |
| 2003-09-30 | 21.25% |
| 2003-06-30 | 19.47% |
| 2003-03-31 | 20.61% |
| 2002-12-31 | 20.68% |
| 2002-09-30 | -18.58% |
| 2002-06-30 | 23.55% |
Related Metrics
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian